Form 4: Xenon CMO Granted 120,000 Equity Awards

Xenon Pharmaceuticals' Chief Medical Officer, Christopher John Kenney, was granted 120,000 equity awards, including stock options and restricted share units, effective January 9, 2026.

Summary

• Christopher John Kenney, Chief Medical Officer of Xenon Pharmaceuticals Inc. (XENE), was granted equity awards on January 9, 2026.
• The awards include 100,000 Share Options (Right to Buy) with an exercise price of $42.15.
• Additionally, 20,000 Restricted Share Units (RSUs) were granted.
• The share options begin vesting 25% on January 9, 2027, with the remaining 75% vesting monthly over the subsequent three years, and expire on January 8, 2036.
• The restricted share units vest 25% on each of the first four anniversaries of the grant date, commencing January 9, 2027.

Sentiment

Score: 7

Explanation: The grant of significant equity awards to a key executive is generally a positive signal, indicating management retention and alignment with shareholder interests, though it's a standard compensation event rather than a performance announcement.

Positives

• The grant of significant equity awards to a key executive like the Chief Medical Officer aligns management's long-term interests with those of shareholders.
• The substantial number of options and RSUs granted indicates a commitment to retaining key talent and confidence in the company's future performance.

Future Outlook

The equity grants, particularly with their multi-year vesting schedules, suggest a long-term commitment from the Chief Medical Officer and an expectation of future value creation for Xenon Pharmaceuticals, aligning executive incentives with sustained company growth.

Industry Context

Equity grants are a standard and widely adopted compensation practice within the pharmaceutical and biotechnology industry. These awards are crucial for attracting, retaining, and motivating key talent, ensuring their incentives are aligned with the long-term success and shareholder value creation of the company.

Comparison to Industry Standards

• Equity compensation packages, including stock options and restricted share units, are common in the pharmaceutical industry for executive retention and motivation.
• The vesting schedules (4 years for RSUs, 4 years for options) are typical for executive compensation plans in biotech, similar to practices seen at companies like Biogen or Regeneron, aiming to ensure long-term commitment.
• The specific value of the grant would need comparison to peer Chief Medical Officer compensation packages, but the structure is standard.

Related Party Transactions

• The equity grant to Christopher John Kenney, Chief Medical Officer, constitutes a related party transaction as it involves compensation from the company to an executive.

Stakeholder Impact

• Shareholders: Potential for future dilution from the exercise of options and vesting of RSUs, balanced by the potential for increased shareholder value if the executive's incentives lead to improved company performance.
• Employees: Standard executive compensation practices can influence overall compensation philosophy and morale within the company.

Next Steps

• The granted share options will begin vesting 25% on January 9, 2027, with the remaining 75% vesting monthly over the subsequent three years.
• The restricted share units will vest 25% on each of the first four anniversaries of the grant date, starting January 9, 2027.

Key Dates

Recommendation

This Form 4 details a routine equity grant to a key executive as part of their compensation package. While it aligns management incentives with shareholder interests, it does not provide new operational or financial performance data to warrant a change in investment recommendation. Investors should consider this as part of ongoing executive compensation disclosures.

Keywords

Xenon Pharmaceuticals, XENE, Form 4, Insider Transaction, Stock Options, Restricted Share Units, Equity Grant, Chief Medical Officer, Christopher John Kenney